Zhi‐Cheng Jin

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 262 citations · Full text

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 119 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +9

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study

Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen et al. · European Radiology · 2023 · 75 citations · Full text

Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study

Zhi‐Cheng Jin, Li Chen, Bin‐Yan Zhong et al. · Translational Oncology · 2021 · 40 citations · Full text

Aloperine induces apoptosis and inhibits invasion in MG-63 and U2OS human osteosarcoma cells

Chen Shao, Zhi‐Cheng Jin, Dai Li et al. · Biomedicine & Pharmacotherapy · 2017 · 34 citations

Tumor Biology, Oncology, Medicine +8